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Abstract
Background: Renal medullary carcinoma (RMC) is a rare kidney tumor that occurs in adolescent and young adults,
typically in association with sickle cell trait. RMC exhibits rapid disease progression, frequent metastases at diagnosis, and
dismal clinical outcomes. Currently available therapies, including cisplatin-based combination chemotherapy, multi-tyrosine
kinase, and mTOR inhibitor strategies demonstrate either transient responses or minimal activity. Therefore,
further molecular characterization and additional treatment strategies are urgently needed in this aggressive disease.
The role of immune system surveillance and responsiveness to anti-PD-1 therapies in RMC are completely unexplored.
Case presentation: A 29 year old male with sickle cell trait presented with painless hematuria that ultimately resulted
in a diagnosis of RMC. He underwent total nephrectomy and adjuvant cytotoxic chemotherapy with carboplatin,
gemcitabine, paclitaxel, and bevacizumab. As is common in this aggressive form of kidney cancer he recurred with
biopsy proven lymph node metastasis. He was started on checkpoint inhibitor therapy with nivolumab that inhibits
program cell death protein 1 (PD-1), and on his first follow-up imaging he was found to have a partial response that
on subsequent scans ultimately resulted in a complete response lasting greater than nine months. In this report, we
present a patient with metastatic RMC who exhibited a clinical response to nivolumab, as well as the genetic and
immunologic correlates of the pre-treatment tumor. Provocatively, robust immune infiltrate and expression of immune
checkpoints were observed, despite the presence of a low mutation burden.
Conclusions: Here, we report the first case of immune microenvironment profiling and response to anti-PD-1 in a
patient with RMC to our knowledge. This case suggests that anti-PD-1 based therapies may have clinical activity in RMC.
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Background
Renal medullary carcinoma (RMC) is a rare cancer often
referred to as the “seventh sickle cell nephropathy” [1].
The typical patient with RMC is an adolescent or young
adult (<40 years old) with sickle cell trait, although other
hemoglobinopathies and patients with sickle cell disease
have also been encountered [2]. Presenting symptoms
include gross hematuria, flank pain, weight loss, fatigue,
and often symptoms of metastatic disease. Imaging at
diagnosis demonstrates mass lesions centered in the
renal medulla, frequently with associated satellite lesions
and metastatic spread. The majority of patients present
with advanced disease at diagnosis, and RMC has a rapid
natural progression of disease with a mean life span with
nephrectomy of 16 months [3, 4].
The biology of RMC is only recently being elucidated.
The most common genetic event that has been observed
is loss of SMARCB1/INI1. This was first recognized in
2008 based on loss of protein expression [5], and gen-
omic analysis revealed allelic loss and inactivation [6].
More recently, balanced translocations in the tumor
suppressor SMARCB1 have been observed as a cause for
this loss [7]. Notably there has been a lack of additional
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genetic alterations and overall these tumors display rela-
tive genome stability [7]. The functional implications of
losing this key Swi/Snf complex member remain uncer-
tain. Importantly, the immunologic characteristics of this
tumor type have not been thoroughly examined,
although one preliminary study suggests that many
RMC tumors express PD-L1 [8]. In particular, the profile
of tumor infiltrating lymphocytes, immune checkpoint
expression, and response to anti-PD-1/PD-L1 have not
been described.
Due the rarity of RMC and its rapid clinical progres-
sion, therapeutic choices are informed by case reports
and small patient series rather than randomized clinical
trials. Several reports have shown that patients with
RMC can transiently respond to combination platinum-
based cytotoxic chemotherapy, but experience little
benefit when treated with VEGF or mTOR inhibitors,
agents that are conventionally used for clear cell renal
cell carcinoma [9–13]. Thus, better therapies for this
disease are urgently needed. Here, we report a clinical
response of a patient with RMC to PD-1 inhibition, and
survey the immunologic characteristics of the pre-
treatment tumor.
Case presentation
A 29 year old previously healthy African American male
with sickle cell trait sought evaluation for new onset
hematuria. Computed tomography (CT) imaging showed
a lesion at the pole of his left kidney and aortocaval
lymphadenopathy; a biopsy was consistent with renal
medullary carcinoma. He underwent an open left partial
nephrectomy with retroperitoneal lymph node dissec-
tion. Surgical pathology showed a 2.2 cm tumor with
positive margins, Fuhrman nuclear grade 4, involvement
of the renal pelvis, and lymphatic invasion with an asso-
ciated mass of lymph nodes measuring 3 cm in diameter
(AJCC stage III – pT1aN1Mx). Next generation sequen-
cing identified only two genomic alterations of known
significance, including the loss of SMARCB1 as a homo-
zyogous copy number deletion, and a frame shift muta-
tion in ARID2 (H1495fs*8).
The patient started an adjuvant treatment regimen of
carboplatin AUC of 4, gemcitabine at 1000 mg/m2, and
paclitaxel at 80 mg/m2 with the addition of bevacizumab.
He experienced significant cytopenias requiring 20%
dose reduction to complete 6 cycles of therapy, after
which he had no evidence of disease based on
imaging. He proceeded with interval cross-sectional
imaging every 3 months and had enlargement of a
para-aortic lymph node consistent with disease recur-
rence within 7 months of completing chemotherapy.
The patient was reluctant to resume chemotherapy at
the time of recurrence due to his prior difficulties
with cytopenias and was offered localized therapy
with intensity-modulated radiation therapy followed
by radiosurgical boost. At completion of his radio-
therapy, PET imaging showed resolution of the para-
aortic lymph node targeted by radiation, but multiple
new enlarged sub-carinal and mediastinal lymph
nodes (Fig. 1a).
He then underwent flexible bronchoscopy and biopsy
of a right paratracheal lymph node that confirmed dis-
ease recurrence. He was initiated on treatment with
nivolumab, a PD-1 inhibitor, at 3 mg/kg every two
weeks. On his initial CT scan, he was found to have an
excellent partial response. At the time of this report, the
patient has continued to tolerate nivolumab well with
only mild fatigue, and has worked full-time throughout
treatment. Now nine months after initiation of PD-1 in-
hibition, his CT scan showed complete response (Fig. 1b)
almost 32 months from the time of his initial diagnosis.
To elucidate the mechanisms and immune correlates
of his response to therapy, we obtained archival tissue
from his metastatic, pre-treatment biopsy of the subcar-
inal lymph node. We performed fluorescent immunohis-
tochemistry using automated quantitative analysis
(AQUA®; Genoptix, Inc) to profile the tumor microenvir-
onment. This assay demonstrated substantial expression
of PD-L1 (E1L3N antibody) by 23% of tumor cells, and
modest expression of both PD-1 and PD-L1 by stromal
components (2% and 5% of cells respectively; Fig. 2).
Robust expression of both CD8 (10% stromal expres-
sion) and CD4 (41% stromal expression) were also dem-
onstrated among infiltrating lymphocytes. Notably, a
high percentage of T cells were also positive for CTLA4
(31%). Total infiltrating T cells comprised 21% of all cells
in the sample. Interestingly, next generation sequencing
of 315 genes (FoundationOne®, Foundation Medicine)
showed an extremely overall low mutational burden
(projected as <1 mutation/MB).
Conclusions
Here, we report the first case of immune microenviron-
ment profiling and response to anti-PD-1 in a patient
with RMC to our knowledge. RMC is a rare subtype of
kidney cancer most commonly diagnosed at advanced
stage with a poor overall survival measured in months.
We present a unique case of a patient diagnosed with
locally advanced disease who underwent surgical resec-
tion followed by adjuvant chemotherapy with subse-
quent rapid disease progression. Radiation to the site of
progression was locally effective but he developed simul-
taneous metastatic spread to multiple mediastinal lymph
nodes thereafter. He initiated treatment with the PD-1
inhibitor nivolumab resulting in complete response
which is ongoing 9 months into therapy. To our know-
ledge, this is the first characterization of immune
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profiling of RMC, and the first case of response to anti-
PD-1 in this disease state.
Nivolumab, a monoclonal antibody inhibiting PD-1,
was recently approved by the FDA as second line treat-
ment for patients with advanced renal cell carcinoma
(RCC). PD-1 is a cell surface signaling receptor found on
chronically stimulated T cells which dampens their
response and provides negative feedback inhibition.
Nivolumab produced a 25% overall response rate com-
pared to 5% with the mTOR inhibitor everolimus in pa-
tients with metastatic RCC, thus becoming one of few
approved drugs to extend overall survival in this disease
(in this case by 5.4 months) [14]. Patients on this and
other immunotherapy clinical trials, however, have pri-
marily included the clear cell subtype; RMC is a rare
enough entity to not have been studied in this arena to
date. There are now numerous ongoing clinical trials
using checkpoint inhibitors targeting PD-1 and its ligand
PD-L1 in new settings including as upfront treatment, in
combination with other checkpoint inhibitors, and in a
rapidly expanding range of malignancies.
Numerous efforts to identify markers that may predict
response to anti-PD-1 are ongoing, including total num-
bers of somatic mutations and markers of immune infil-
trate (particularly CD8, PD-1, PD-L1, and CTLA-4).
High overall mutational burden in various tumor types
including colon cancer with mismatch repair deficiency,
non-small cell lung cancer, urothelial bladder cancer,
and melanoma has also been suggested as a predictive
biomarker of response to checkpoint inhibition [15–18].
By contrast, whole exome sequencing and next gener-
ation gene panel approaches have found that RMC tu-
mors are genomically quite stable. One could speculate
that epigenetic modification, stemming from loss of
SMARCB1, leads to presentation of neoantigens trigger-
ing responses to PD-1 inhibition [19–21]. Mutations in
ARID2 like that found in our patient, have been ideniti-
fied to occur in up to 10% of papillary renal cell carcin-
oma [22]. Interestingly, ARID2 is also a member of the
SWI/SNF chromatin remodeling complex which sug-
gests that loss of function of this complex is important
in the pathophysiology of RMC and could lead to
Fig. 1 Response to PD-1 inhibition in patient with renal medullary carcinoma. a CT chest with contrast showing mediastinal lymphadenopathy prior to
treatment with nivolumab (b) CT chest with contrast showing resolution of mediastinal lymphadenopathy after nine months on treatment with nivolumab
Fig. 2 Immunologic correlates by automated quantitative analysis. a 20x, DAPI in blue, cytokeratin in green, PD-1 in yellow, and PD-L1 in red. b 20x, DAPI
blue, cytokeratin yellow, CD8 green, and CD4 red
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enhanced presentation of neoantigens. Notably, our patient
was found to have a vigorous immune infiltrate including
CD4+ and CD8+ T cells and high levels of immune check-
point expression, including PD-L1, CTLA-4, and PD-1,
which suggest pre-existing immune recognition, and have
also been linked to immune therapy responses [23–25]. By
contrast, the patient was found to have a very low calcu-
lated mutation burden using targeted next generation se-
quencing. Thus, this study suggests alternative paradigms
of immune responsiveness beyond mutational load.
In an adolescent and young adult disease such as
RMC where median overall survival is 16 months and
current treatment options are suboptimal, additional
biologic insights and novel therapeutics are urgently
needed. This case report suggests a potential role for
PD-1/PD-L1 inhibition in RMC. Further investigation in
RMC and other rare RCC subtypes is necessary to deter-
mine the benefit of immune checkpoint inhibitors in
patients with various subtypes of kidney cancer.
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